Apricus Biosciences Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/13/2018)
| Balance Sheet | Total Assets | 11,096,000.00 | ROE | – |
| Balance Sheet | Total Equity | -7,000.00 | ROA | – |
| Cashflow | Capital Expenditures | 8,126,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -19,305,000.00 | – | – |
| Cashflow | Operating Cash Flow | -19,305,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -2.52 | Div. Yield | – |
| Income | Net Income | -51,255,000.00 | P/E | – |
| Income | Shares Outstanding | 15,220,000.00 | P/B | – |
| Income | Total Revenue | 375,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Apricus Biosciences, Inc. is in the pharmaceutical industry primarily focusing on research and development using its drug delivery technology called NexACT. The Company is actively engaged in acquiring companies and in-licensing drugs that will complement its product portfolio.The Company´s pipeline of approved and late stage NexACT based product candidates includes Vitaros, which is approved in Canada for the treatment of erectile dysfunction, Femprox for female sexual arousal disorder, MycoVa for onychomycosis excluding tinea pedis (nail fungal infection), RayVa for Raynaud´s Syndrome and PrevOnco for liver cancer. The Company´s pipeline of late stage preclinical products includes Nupen for post-chemotherapy recovery of Neutrophil. In June, 2011, the Company sold Bio-Quant, Inc. (Bio-Quant). On December 29, 2011, the Company acquired Topotarget USA, Inc. In April 2013, the Company announced the sale of Totect (dexrazoxane HCl), and NitroMist (nitroglycerin sublingual aerosol).
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.apricusbio.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more